There is if and buts, assumptions all through that post of yours Rinnekin - the blurred explanation of the point, you are trying to make - could in fact be taken as endorsement of my 50%. Why not read what you have said again ?
My post is an accurate assumption. It is in line with the company's latest general comment - other positives about paxalisib in GBM, from that Patrick Wen & others abstract.
Of NOTE - way back in 2011 NOVOCURE product, only matched Temozolomide in OS, but was approved - the FDA will look at more than just matching existing standard of care - exactly what was purposely alluded to by Dr Wen in the abstract .
Pivotal Trial Results
The FDA approval was based on data from a randomized pivotal trial of 237 patients with glioblastoma tumors that had recurred or progressed despite previous surgical, radiation and chemotherapy treatments. Patients treated with the NovoTTF alone achieved a comparable overall survival time to patients treated with the physician's choice of the best chemotherapy. The rate of progression free survival at six months (PFS6) was 21 percent in the NovoTTF group compared to 15 percent in chemotherapy patients.
Maybe Rinnekin - based on your views - you can get back to the company to update this ASX announcement from only June 2022.
• Median overall survival (OS) in the intent-to-treat (ITT) population (n=30) was 15.7 months (11.1 – 19.1), which compares very favourably to the figure of 12.7 months historically reported with temozolomide in this patient group.1
KZA Price at posting:
8.3¢ Sentiment: Hold Disclosure: Held
